- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
Patent holdings for IPC class A61P 3/08
Total number of patents in this class: 1210
10-year publication summary
|
33
|
67
|
95
|
85
|
80
|
86
|
64
|
81
|
79
|
14
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Pharmaceutica N.V. | 3267 |
23 |
| The Board of Trustees of the Leland Stanford Junior University | 6604 |
16 |
| Boehringer Ingelheim International GmbH | 4569 |
14 |
| Axcess Global Sciences, LLC | 89 |
13 |
| TNF Pharmaceuticals, Inc. | 19 |
11 |
| Sanofi-Aventis Deutschland GmbH | 2611 |
10 |
| Société des Produits Nestlé S.A. | 9946 |
9 |
| The Regents of the University of California | 20494 |
9 |
| Alla Chem, LLC | 52 |
9 |
| Eli Lilly and Company | 4007 |
9 |
| Amgen Inc. | 4323 |
8 |
| The Trustees of Columbia University in the City of New York | 3621 |
7 |
| Takeda Pharmaceutical Company Limited | 2728 |
7 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3350 |
7 |
| Regeneron Pharmaceuticals, Inc. | 4569 |
7 |
| Novo Nordisk A/S | 2283 |
7 |
| Atrogi AB | 57 |
6 |
| Hanmi Pharm. Co., Ltd. | 590 |
6 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3112 |
6 |
| Ionis Pharmaceuticals, Inc. | 930 |
6 |
| Other owners | 1020 |